1387 related articles for article (PubMed ID: 8603815)
21. c-fos and c-jun overexpression in malignant cells reduces their tumorigenic and metastatic potential, and affects their MHC class I gene expression.
Yamit-Hezi A; Plaksin D; Eisenbach L
Oncogene; 1994 Apr; 9(4):1065-79. PubMed ID: 8134110
[TBL] [Abstract][Full Text] [Related]
22. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
[TBL] [Abstract][Full Text] [Related]
23. Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells.
Porgador A; Tzehoval E; Katz A; Vadai E; Revel M; Feldman M; Eisenbach L
Cancer Res; 1992 Jul; 52(13):3679-86. PubMed ID: 1617640
[TBL] [Abstract][Full Text] [Related]
24. Coexpression of interleukin-4 and B7.1 in murine tumor cells leads to improved tumor rejection and vaccine effect compared to single gene transfectants and a classical adjuvant.
Cayeux S; Beck C; Dörken B; Blankenstein T
Hum Gene Ther; 1996 Mar; 7(4):525-9. PubMed ID: 8800747
[TBL] [Abstract][Full Text] [Related]
25. B7-1 expression decreases tumorigenicity and induces partial systemic immunity to murine neuroblastoma deficient in major histocompatibility complex and costimulatory molecules.
Katsanis E; Xu Z; Bausero MA; Dancisak BB; Gorden KB; Davis G; Gray GS; Orchard PJ; Blazar BR
Cancer Gene Ther; 1995 Mar; 2(1):39-46. PubMed ID: 7542553
[TBL] [Abstract][Full Text] [Related]
26. H-2K double transfectants of tumor cells as antimetastatic cellular vaccines in heterozygous recipients. Implications for the T cell repertoire.
Mandelboim O; Feldman M; Eisenbach L
J Immunol; 1992 Jun; 148(11):3666-73. PubMed ID: 1588053
[TBL] [Abstract][Full Text] [Related]
27. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity.
Todo T; Martuza RL; Dallman MJ; Rabkin SD
Cancer Res; 2001 Jan; 61(1):153-61. PubMed ID: 11196154
[TBL] [Abstract][Full Text] [Related]
28. Enhanced immunogenicity of B cell lymphoma genetically engineered to express both B7-1 and interleukin-12.
Pizzoferrato E; Chu NR; Hawley TS; Lieu FH; Barber BH; Hawley RG; Watts TH; Berinstein NL
Hum Gene Ther; 1997 Dec; 8(18):2217-28. PubMed ID: 9449375
[TBL] [Abstract][Full Text] [Related]
29. Effective anti-metastatic melanoma vaccination with tumor cells transfected with MHC genes and/or infected with Newcastle disease virus (NDV).
Plaksin D; Porgador A; Vadai E; Feldman M; Schirrmacher V; Eisenbach L
Int J Cancer; 1994 Dec; 59(6):796-801. PubMed ID: 7989121
[TBL] [Abstract][Full Text] [Related]
30. B7-1 and interleukin 12 synergistically induce effective antitumor immunity.
Coughlin CM; Wysocka M; Kurzawa HL; Lee WM; Trinchieri G; Eck SL
Cancer Res; 1995 Nov; 55(21):4980-7. PubMed ID: 7585539
[TBL] [Abstract][Full Text] [Related]
31. CIGB-247: a VEGF-based therapeutic vaccine that reduces experimental and spontaneous lung metastasis of C57Bl/6 and BALB/c mouse tumors.
Bequet-Romero M; Morera Y; Ayala-Ávila M; Ancizar J; Soria Y; Blanco A; Suárez-Alba J; Gavilondo JV
Vaccine; 2012 Feb; 30(10):1790-9. PubMed ID: 22240345
[TBL] [Abstract][Full Text] [Related]
32. In vivo immunogenicity of osteosarcoma cells that express B7-1a, an alternatively spliced form of B7-1.
Nagamori M; Kawaguchi S; Murakami M; Wada T; Inobe M; Ishii S; Uede T
Anticancer Res; 2002; 22(4):2009-13. PubMed ID: 12174878
[TBL] [Abstract][Full Text] [Related]
33. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine.
Guinn BA; DeBenedette MA; Watts TH; Berinstein NL
J Immunol; 1999 Apr; 162(8):5003-10. PubMed ID: 10202049
[TBL] [Abstract][Full Text] [Related]
34. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines.
Pulaski BA; Ostrand-Rosenberg S
Cancer Res; 1998 Apr; 58(7):1486-93. PubMed ID: 9537252
[TBL] [Abstract][Full Text] [Related]
35. Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization.
Gajewski TF; Fallarino F; Uyttenhove C; Boon T
J Immunol; 1996 Apr; 156(8):2909-17. PubMed ID: 8609411
[TBL] [Abstract][Full Text] [Related]
36. Simultaneous expression of allogenic class II MHC and B7.1 (CD80) molecules in A20 B-lymphoma cell line enhances tumor immunogenicity.
Jang YJ; Nam SY; Kim MS; Seong RH; Park YS; Chung YH; Chung HY
Mol Cells; 2002 Feb; 13(1):130-6. PubMed ID: 11911464
[TBL] [Abstract][Full Text] [Related]
37. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
Wang J; Saffold S; Cao X; Krauss J; Chen W
J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
[TBL] [Abstract][Full Text] [Related]
38. [Rejection of non-immunogenic tumor cells transfected with costimulatory molecule B7 after treatment with IFN-gamma in vitro].
Zheng S; Zhang S; Wang D
Zhonghua Zhong Liu Za Zhi; 1998 Sep; 20(5):333-6. PubMed ID: 10921023
[TBL] [Abstract][Full Text] [Related]
39. Adenoviral B7-H3 therapy induces tumor specific immune responses and reduces secondary metastasis in a murine model of colon cancer.
Lupu CM; Eisenbach C; Lupu AD; Kuefner MA; Hoyler B; Stremmel W; Encke J
Oncol Rep; 2007 Sep; 18(3):745-8. PubMed ID: 17671729
[TBL] [Abstract][Full Text] [Related]
40. Immunoregulation by B7 and IL-12 gene transfer.
Kato K; Okumura K; Yagita H
Leukemia; 1997 Apr; 11 Suppl 3():572-6. PubMed ID: 9209458
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
